Patient Assessment of Foam Attributes from the Tazarotene Foam, 0.1%, Phase III Trials and Potential Impact on Patient Compliance. (2018). SKIN The Journal of Cutaneous Medicine, 2, S57. https://doi.org/10.25251/skin.2.supp.57